{
    "analytics_identifier":  null,
    "base_path":  "/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-after-brexit",
    "content_id":  "eb7f4a76-7508-478c-84a5-33abacdce842",
    "description":  "This guidance provides further information on comparator products used in studies supporting abridged marketing authorisation applications in a no-deal Brexit.",
    "details":  {
                    "attachments":  [

                                    ],
                    "body":  "\u003cdiv class=\"govspeak\"\u003e\n\u003ch2 id=\"introduction\"\u003eIntroduction\u003c/h2\u003e\n\n\u003ch3 id=\"reference-medicinal-product\"\u003eReference Medicinal Product\u003c/h3\u003e\n\n\u003cp\u003eIn January 2019, \u003cabbr title=\"Medicines and Healthcare products Regulatory Agency\"\u003eMHRA\u003c/abbr\u003e and the Department of Health and Social Care published \u003ca href=\"https://www.gov.uk/government/publications/further-guidance-note-on-the-regulation-of-medicines-medical-devices-and-clinical-trials-if-theres-no-brexit-deal/further-guidance-note-on-the-regulation-of-medicines-medical-devices-and-clinical-trials-if-theres-no-brexit-deal\" class=\"govuk-link\"\u003efurther guidance on how medicines, medical devices and clinical trials will be regulated\u003c/a\u003e if the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e leaves the \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e without a deal.\u003c/p\u003e\n\n\u003cp\u003eIn a no-deal Brexit, \u003ca href=\"https://www.gov.uk/guidance/guidance-on-reference-medicinal-products-rmps-if-the-uk-leaves-the-eu-without-a-deal\" class=\"govuk-link\"\u003ereference medicinal products (\u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e)\u003c/a\u003e for new generic medicines or other abridged marketing authorisation applications submitted after exit day will be required to comply with the relevant legislation.\u003c/p\u003e\n\n\u003cp\u003eThis legislation is the \u003ca rel=\"external\" href=\"http://www.legislation.gov.uk/ukdsi/2019/9780111179185/contents\" class=\"govuk-link\"\u003eHuman Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc.) (\u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e Exit) Regulations 2019 (\u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)\u003c/a\u003e, in particular regulations 48 and 51 to 55.\u003c/p\u003e\n\n\u003cp\u003eEligible products will also include:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eProducts that are or have been authorised for at least 8 years in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e (including those authorised by conversion from \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e marketing authorisations)\u003c/li\u003e\n  \u003cli\u003eProducts in relation to which an \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e marketing authorisation was in force on exit day, but which did not convert into \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e marketing authorisations as the holder opted out of that process\u003c/li\u003e\n  \u003cli\u003eProducts in relation to which an \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e marketing authorisation had ceased to be in force before exit day for reasons not relating to safety, quality or efficacy\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch3 id=\"comparator-products-used-in-bioequivalence-and-therapeutic-equivalence-studies\"\u003eComparator products used in bioequivalence and therapeutic equivalence studies\u003c/h3\u003e\n\n\u003cp\u003eComparator products (\u003cabbr title=\"Comparator products\"\u003eCPs\u003c/abbr\u003e) used in bioequivalence (\u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e), pharmacokinetic (\u003cabbr title=\"Pharmacokinetic\"\u003ePK\u003c/abbr\u003e) and therapeutic equivalence (\u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e) studies supporting abridged applications should be representative of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e supporting the application.\u003c/p\u003e\n\n\u003cp\u003eGenerally, the \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e should be sourced from the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e. However, if the \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e is not sourced from the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e market, the applicant should provide evidence that it is representative of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e. This guidance document provides further information on the data required to demonstrate this.\u003c/p\u003e\n\n\u003ch2 id=\"scope\"\u003eScope\u003c/h2\u003e\n\n\u003cp\u003eWith the aim of facilitating the global development of medicinal products and to avoid unnecessary repetition of clinical \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies, it may be possible for an applicant to compare the proposed medicinal product with a non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e sourced \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e. The application would still be required to refer to an eligible \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eThe purpose of demonstrating pharmaceutical equivalence and \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e against the \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e is to provide evidence that the safety and efficacy profiles of the proposed product will be equivalent to that of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e and for which safety and efficacy has been demonstrated clinically.\u003c/p\u003e\n\n\u003cp\u003eIn order to determine the acceptability of this evidence, the licensing authority must be satisfied that a non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e is representative of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e and that any differences between these two products would not be therapeutically significant.\u003c/p\u003e\n\n\u003cp\u003eThe following types of abridged applications are commonly supported by \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e or \u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies and are within the scope of this guidance:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eApplications relating to generic medicinal products (regulation 51 \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e), equivalent to Article 10(1) of \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e Directive 2001/83\u003c/li\u003e\n  \u003cli\u003eApplications relating to certain medicinal products that do not qualify as generics etc (regulation 52 \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e), equivalent to Article 10(3) of \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e Directive 2001/83\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThis guidance applies to \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e, \u003cabbr title=\"Pharmacokinetic\"\u003ePK\u003c/abbr\u003e and \u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies provided in support of applications made under any of the above legal bases. In case of complex products, it is recommended that we are consulted for specific advice.\u003c/p\u003e\n\n\u003cp\u003eThe principles may also be applicable to \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e, \u003cabbr title=\"Pharmacokinetic\"\u003ePK\u003c/abbr\u003e or \u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies conducted in support of other applications that are out of the scope of this guidance such as:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eApplications relating to products in well-established medicinal use (regulation 54 \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e), equivalent to Article 10a of \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e Directive 2001/83\u003c/li\u003e\n  \u003cli\u003eApplications relating to new combinations of active substances (regulation 55 \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e), equivalent to Article 10b of \u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e Directive 2001/83\u003c/li\u003e\n  \u003cli\u003eVariations requiring demonstration of \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e to the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e (e.g. for modified release solid oral dosage forms) (regulation 65C \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)\u003c/li\u003e\n  \u003cli\u003eExtension applications (regulation 65C \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThese principles may be applicable to certain non-clinical studies, for example those provided in support of “hybrid” applications.\u003c/p\u003e\n\n\u003cp\u003eIf the use of a non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e is proposed for applications that are out of the scope of this guidance, early discussion with us is recommended to obtain the relevant advice.\u003c/p\u003e\n\n\u003cp\u003eApplications relating to similar biological medical products (regulation 53 \u003cabbr title=\"Human Medicines (Amendment etc.) (EU Exit) Regulations 2019\"\u003eHMRs\u003c/abbr\u003e) are out of scope of this guidance.\u003c/p\u003e\n\n\u003cp\u003eThis guidance should always be read in conjunction with relevant scientific guidelines and legislative provisions in force in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003ch2 id=\"general-principles\"\u003eGeneral principles\u003c/h2\u003e\n\n\u003cp\u003eThe general principles that are applicable are described below. For more specific guidance, especially for more complex dosage forms, it is recommended that the applicant seeks scientific advice from us.\u003c/p\u003e\n\n\u003ch3 id=\"responsibility\"\u003eResponsibility\u003c/h3\u003e\n\n\u003cp\u003eIt will be the applicant’s responsibility to demonstrate that any \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e authorised and sourced from outside the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e is representative of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e authorised in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003ch3 id=\"source-country-of-non-uk-cp\"\u003eSource country of non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e\n\u003c/h3\u003e\n\n\u003cp\u003eThe non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e should be authorised in and sourced from a country with similar scientific and regulatory standards as the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e. Examples would be:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cabbr title=\"European Union\"\u003eEU\u003c/abbr\u003e/\u003cabbr title=\"European Economic Area\"\u003eEEA\u003c/abbr\u003e countries\u003c/li\u003e\n  \u003cli\u003eSwitzerland\u003c/li\u003e\n  \u003cli\u003e\u003cabbr title=\"United States of America\"\u003eUSA\u003c/abbr\u003e\u003c/li\u003e\n  \u003cli\u003eCanada\u003c/li\u003e\n  \u003cli\u003eAustralia\u003c/li\u003e\n  \u003cli\u003eJapan\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e would normally be expected to be:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003epart of the same global marketing authorisation (\u003cabbr title=\"Global Marketing Authorisation\"\u003eGMA\u003c/abbr\u003e) as the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e, or\u003c/li\u003e\n  \u003cli\u003emarketed in the country of origin through a licensing arrangement with the innovator company or corporate entity that currently markets the medicine in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe \u003cabbr title=\"Global Marketing Authorisation\"\u003eGMA\u003c/abbr\u003e contains the initial authorisation and all variations and extensions. It includes any additional strengths, pharmaceutical form, administration routes or presentations authorised through separate procedures and under a different name, granted to the Marketing Authorisation Holder of the initial authorisation.\u003c/p\u003e\n\n\u003ch3 id=\"identicality-vs-representativeness\"\u003eIdenticality vs. representativeness\u003c/h3\u003e\n\n\u003cp\u003eThe non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e used is required to be representative of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e, but it is not required to be identical to it. This means that certain minor differences between both products may be accepted if justified, provided this is supported by bridging data (see below).\u003c/p\u003e\n\n\u003cp\u003eThese differences could include:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eColour of tablet coatings (assuming no difference in functionality of coat) or capsule shells\u003c/li\u003e\n  \u003cli\u003eScorelines, embossings and imprintings on solid dosage forms\u003c/li\u003e\n  \u003cli\u003eFlavours in liquid dosage forms\u003c/li\u003e\n  \u003cli\u003eContainer closures\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003ch3 id=\"demonstration-of-identicality-of-the-non-uk-cp-to-the-uk-rmp\"\u003eDemonstration of identicality of the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e to the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e\n\u003c/h3\u003e\n\n\u003cp\u003eIn cases where the applicant provides written confirmation from the Marketing Authorisation Holder (\u003cabbr title=\"Marketing Authorisation Holder\"\u003eMAH\u003c/abbr\u003e) of the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e that the \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e is identical to the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e, no further analytical data are required.\u003c/p\u003e\n\n\u003cp\u003eThis written confirmation should confirm the following are identical in both products:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ethe route of synthesis of the drug substance(s)\u003c/li\u003e\n  \u003cli\u003ethe drug substance specifications\u003c/li\u003e\n  \u003cli\u003ethe finished product quantitative composition\u003c/li\u003e\n  \u003cli\u003ethe manufacturing process including in-process controls\u003c/li\u003e\n  \u003cli\u003ethe finished product specifications\u003c/li\u003e\n  \u003cli\u003ethe stability data\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eIn cases where identicality can be confirmed, the use of a non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e is also acceptable for more complex formulations.\u003c/p\u003e\n\n\u003cp\u003eFor the drug substance and finished products specifications, non-significant differences in specifications may be acceptable if fully justified.\u003c/p\u003e\n\n\u003ch3 id=\"demonstration-of-representativeness-of-the-non-uk-cp-to-the-uk-rmp\"\u003eDemonstration of representativeness of the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e to the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e\n\u003c/h3\u003e\n\n\u003cp\u003eIf a \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e authorised and sourced from outside the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e is used, the applicant should provide adequate data or information to scientifically justify the relevance of these comparative data and establish an acceptable bridge to the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003cp\u003eAs a scientific matter, the type of bridging data needed should always include data from analytical studies that compare all 3 products:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eBetween the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e and the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e to establish suitability of the latter as \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e in \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies\u003c/li\u003e\n  \u003cli\u003eBetween the proposed medicinal product and the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e to demonstrate similarity to allow bridging of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e data\u003c/li\u003e\n  \u003cli\u003eBetween the proposed medicinal product and the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e to support the \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e/\u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eAny observed differences in the data have to be duly justified with regard to their potential impact on safety and efficacy.\u003c/p\u003e\n\n\u003cp\u003eOnly data requirements between the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e and the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e are discussed here; for other data requirements see current guidance.\u003c/p\u003e\n\n\u003cp\u003eThe following information should be provided in Module 1.5.2 of the Common Technical Dossier structure for both the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e and non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e:\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eName and address of the authorisation holder of the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e used, the product name, the country of authorisation, country of origin, and authorisation number\u003c/li\u003e\n  \u003cli\u003eProof of purchase (batch number, date and place of purchase, expiry date)\u003c/li\u003e\n  \u003cli\u003eSamples in their original container closure systems should be available upon request\u003c/li\u003e\n  \u003cli\u003eProduct information (Summary of Product Characteristics or equivalent)\u003c/li\u003e\n  \u003cli\u003eCertificates of analysis (tested according to the proposed specification for the proposed medicinal product)\u003c/li\u003e\n  \u003cli\u003eThe excipients in the formulation of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e, when compared to the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e, should be qualitatively the same. Any differences in excipients would need to be shown to have no effect on safety or efficacy\u003c/li\u003e\n  \u003cli\u003eIf quantitative formulation information is available for these two products it should also show the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e to be representative of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe experimental comparison should include the physico-chemical properties and all critical product attributes of the medicinal product; these should include device attributes where appropriate. Where provided, dissolution data should cover the physiological pH range. Reference is also made to existing current guidance.\u003c/p\u003e\n\n\u003ch3 id=\"number-of-batches-to-be-tested\"\u003eNumber of batches to be tested\u003c/h3\u003e\n\n\u003cp\u003eFor the comparison between the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e and the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e, data on at least 3 batches of each product would usually be expected.\u003c/p\u003e\n\n\u003cp\u003eIn cases of products that exhibit a higher inherent batch-to-batch variability or that are complex, a larger number of batches might be required to establish representativeness.\u003c/p\u003e\n\n\u003ch3 id=\"analytical-methods\"\u003eAnalytical methods\u003c/h3\u003e\n\n\u003cp\u003eThe precision and accuracy of the analytical methods and the inter-batch variability are critical to deciding if the formulations of the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e and non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e are representative of each other. The analytical methods and analytical method validation reports used to generate the physicochemical data should be provided to satisfy this requirement.\u003c/p\u003e\n\n\u003ch3 id=\"if-the-rmp-is-unavailable\"\u003eIf the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e is unavailable\u003c/h3\u003e\n\n\u003cp\u003eShould the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e not be marketed in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e and not be available for the relevant comparison, the applicant should contact us for advice.\u003c/p\u003e\n\n\u003ch3 id=\"acceptability-of-approach\"\u003eAcceptability of approach\u003c/h3\u003e\n\n\u003cp\u003eThe overall acceptability of such an approach and the type of bridging data needed will be a case-by-case/product-type decision and is recommended to be discussed upfront with the us.\u003c/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003edoes not exhibit immediate release of the drug substance\u003c/li\u003e\n  \u003cli\u003eis not for oral administration\u003c/li\u003e\n  \u003cli\u003eis made by complex methods of manufacture\u003c/li\u003e\n  \u003cli\u003eexhibits a narrow therapeutic range or safety margin (for example, careful dosage titration or patient monitoring)\u003c/li\u003e\n  \u003cli\u003ehas a steep dose-response relationship\u003c/li\u003e\n  \u003cli\u003ea risk of serious undesired effects\u003c/li\u003e\n  \u003cli\u003ecomplicated or variable pharmacokinetics (such as nonlinear pharmacokinetics, variable or incomplete absorption)\u003c/li\u003e\n  \u003cli\u003ean absorption window (i.e. site-specific absorption)\u003c/li\u003e\n  \u003cli\u003esubstantial (e.g. greater than 40%) first-pass metabolism\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eHowever, the final determination of the adequacy of the scientific justification and bridging will only be made during the assessment of the application. This will take the safety, efficacy and quality of the medicinal product into account.\u003c/p\u003e\n\n\u003cp\u003eIf representativeness between the non-\u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e \u003cabbr title=\"Comparator product\"\u003eCP\u003c/abbr\u003e and the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e cannot be demonstrated, \u003cabbr title=\"Bioequivalence]\"\u003eBE\u003c/abbr\u003e and \u003cabbr title=\"Therapeutic equivalence\"\u003eTE\u003c/abbr\u003e studies should be performed against the \u003cabbr title=\"Reference medicinal products\"\u003eRMP\u003c/abbr\u003e in the \u003cabbr title=\"United Kingdom\"\u003eUK\u003c/abbr\u003e.\u003c/p\u003e\n\n\u003c/div\u003e",
                    "change_history":  [
                                           {
                                               "note":  "First published.",
                                               "public_timestamp":  "2019-10-22T16:28:00.000+01:00"
                                           }
                                       ],
                    "emphasised_organisations":  [
                                                     "240f72bd-9a4d-4f39-94d9-77235cadde8e"
                                                 ],
                    "first_public_at":  "2019-10-22T16:28:00.000+01:00",
                    "political":  false,
                    "related_mainstream_content":  [

                                                   ],
                    "tags":  {
                                 "browse_pages":  [

                                                  ],
                                 "topics":  [
                                                "6d1048f5-9d18-4045-8562-9b85c71b1c9e"
                                            ]
                             }
                },
    "document_type":  "detailed_guide",
    "first_published_at":  "2019-10-22T16:28:00+01:00",
    "links":  {
                  "available_translations":  [
                                                 {
                                                     "api_path":  "/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-after-brexit",
                                                     "api_url":  "https://www.gov.uk/api/content/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-after-brexit",
                                                     "base_path":  "/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-after-brexit",
                                                     "content_id":  "eb7f4a76-7508-478c-84a5-33abacdce842",
                                                     "document_type":  "detailed_guide",
                                                     "links":  {

                                                               },
                                                     "locale":  "en",
                                                     "public_updated_at":  "2019-10-22T15:28:00Z",
                                                     "schema_name":  "detailed_guide",
                                                     "title":  "Comparator products in Bioequivalence/Therapeutic Equivalence studies after Brexit",
                                                     "web_url":  "https://www.gov.uk/guidance/comparator-products-in-bioequivalencetherapeutic-equivalence-studies-after-brexit",
                                                     "withdrawn":  true
                                                 }
                                             ],
                  "government":  [
                                     {
                                         "api_path":  "/api/content/government/2015-conservative-government",
                                         "api_url":  "https://www.gov.uk/api/content/government/2015-conservative-government",
                                         "base_path":  "/government/2015-conservative-government",
                                         "content_id":  "d4fbc1b9-d47d-4386-af04-ac909f868f92",
                                         "details":  {
                                                         "current":  false,
                                                         "ended_on":  "2016-07-13T00:00:00+00:00",
                                                         "started_on":  "2015-05-08T00:00:00+00:00"
                                                     },
                                         "document_type":  "government",
                                         "links":  {

                                                   },
                                         "locale":  "en",
                                         "title":  "2015 to 2016 Cameron Conservative government",
                                         "web_url":  "https://www.gov.uk/government/2015-conservative-government"
                                     }
                                 ],
                  "organisations":  [
                                        {
                                            "analytics_identifier":  "EA63",
                                            "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                            "details":  {
                                                            "acronym":  "MHRA",
                                                            "brand":  "department-of-health",
                                                            "default_news_image":  null,
                                                            "logo":  {
                                                                         "crest":  "single-identity",
                                                                         "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                     },
                                                            "organisation_govuk_status":  {
                                                                                              "status":  "live",
                                                                                              "updated_at":  null,
                                                                                              "url":  null
                                                                                          }
                                                        },
                                            "document_type":  "organisation",
                                            "links":  {

                                                      },
                                            "locale":  "en",
                                            "schema_name":  "organisation",
                                            "title":  "Medicines and Healthcare products Regulatory Agency",
                                            "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                            "withdrawn":  false
                                        }
                                    ],
                  "original_primary_publishing_organisation":  [
                                                                   {
                                                                       "analytics_identifier":  "EA63",
                                                                       "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                                       "details":  {
                                                                                       "acronym":  "MHRA",
                                                                                       "brand":  "department-of-health",
                                                                                       "default_news_image":  null,
                                                                                       "logo":  {
                                                                                                    "crest":  "single-identity",
                                                                                                    "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                                },
                                                                                       "organisation_govuk_status":  {
                                                                                                                         "status":  "live",
                                                                                                                         "updated_at":  null,
                                                                                                                         "url":  null
                                                                                                                     }
                                                                                   },
                                                                       "document_type":  "organisation",
                                                                       "links":  {

                                                                                 },
                                                                       "locale":  "en",
                                                                       "schema_name":  "organisation",
                                                                       "title":  "Medicines and Healthcare products Regulatory Agency",
                                                                       "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                                       "withdrawn":  false
                                                                   }
                                                               ],
                  "primary_publishing_organisation":  [
                                                          {
                                                              "analytics_identifier":  "EA63",
                                                              "api_path":  "/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "api_url":  "https://www.gov.uk/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "base_path":  "/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "content_id":  "240f72bd-9a4d-4f39-94d9-77235cadde8e",
                                                              "details":  {
                                                                              "acronym":  "MHRA",
                                                                              "brand":  "department-of-health",
                                                                              "default_news_image":  null,
                                                                              "logo":  {
                                                                                           "crest":  "single-identity",
                                                                                           "formatted_title":  "Medicines \u0026amp; Healthcare products\u003cbr/\u003eRegulatory Agency"
                                                                                       },
                                                                              "organisation_govuk_status":  {
                                                                                                                "status":  "live",
                                                                                                                "updated_at":  null,
                                                                                                                "url":  null
                                                                                                            }
                                                                          },
                                                              "document_type":  "organisation",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "schema_name":  "organisation",
                                                              "title":  "Medicines and Healthcare products Regulatory Agency",
                                                              "web_url":  "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "suggested_ordered_related_items":  [
                                                          {
                                                              "api_path":  "/api/content/government/publications/the-governments-response-to-the-acmds-further-advice-on-synthetic-cannabinoids-and-advice-on-methoxetamine-and-related-compounds-as-well-as-o-desmethyltramadol",
                                                              "api_url":  "https://www.gov.uk/api/content/government/publications/the-governments-response-to-the-acmds-further-advice-on-synthetic-cannabinoids-and-advice-on-methoxetamine-and-related-compounds-as-well-as-o-desmethyltramadol",
                                                              "base_path":  "/government/publications/the-governments-response-to-the-acmds-further-advice-on-synthetic-cannabinoids-and-advice-on-methoxetamine-and-related-compounds-as-well-as-o-desmethyltramadol",
                                                              "content_id":  "5d818b97-7631-11e4-a3cb-005056011aef",
                                                              "document_type":  "correspondence",
                                                              "links":  {

                                                                        },
                                                              "locale":  "en",
                                                              "public_updated_at":  "2012-11-01T00:00:00Z",
                                                              "schema_name":  "publication",
                                                              "title":  "The Government\u0027s response to the ACMD\u0027s further advice on synthetic cannabinoids and advice on methoxetamine and related compounds as well as O-desmethyltramadol.",
                                                              "web_url":  "https://www.gov.uk/government/publications/the-governments-response-to-the-acmds-further-advice-on-synthetic-cannabinoids-and-advice-on-methoxetamine-and-related-compounds-as-well-as-o-desmethyltramadol",
                                                              "withdrawn":  false
                                                          }
                                                      ],
                  "taxons":  [
                                 {
                                     "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "base_path":  "/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "content_id":  "f4f28e9d-2050-45fb-ab76-78c0345670da",
                                     "details":  {
                                                     "internal_name":  "Marketing authorisations, variations and licensing guidance [T]",
                                                     "notes_for_editors":  "",
                                                     "visible_to_departmental_editors":  false
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "api_url":  "https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood",
                                                                             "base_path":  "/health-and-social-care/medicines-medical-devices-blood",
                                                                             "content_id":  "cebc01ee-f70a-4397-a552-622e10b62508",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Medicines and medical devices [T] (level 2, health theme)",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  false
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "parent_taxons":  [
                                                                                                                 {
                                                                                                                     "api_path":  "/api/content/health-and-social-care",
                                                                                                                     "api_url":  "https://www.gov.uk/api/content/health-and-social-care",
                                                                                                                     "base_path":  "/health-and-social-care",
                                                                                                                     "content_id":  "8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8",
                                                                                                                     "description":  "",
                                                                                                                     "details":  {
                                                                                                                                     "internal_name":  "Health and social care",
                                                                                                                                     "notes_for_editors":  "",
                                                                                                                                     "visible_to_departmental_editors":  true
                                                                                                                                 },
                                                                                                                     "document_type":  "taxon",
                                                                                                                     "links":  {
                                                                                                                                   "root_taxon":  ""
                                                                                                                               },
                                                                                                                     "locale":  "en",
                                                                                                                     "phase":  "live",
                                                                                                                     "public_updated_at":  "2018-09-16T20:30:51Z",
                                                                                                                     "schema_name":  "taxon",
                                                                                                                     "title":  "Health and social care",
                                                                                                                     "web_url":  "https://www.gov.uk/health-and-social-care",
                                                                                                                     "withdrawn":  false
                                                                                                                 }
                                                                                                             ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2019-02-06T16:16:55Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Medicines, medical devices",
                                                                             "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2018-08-22T12:56:21Z",
                                     "schema_name":  "taxon",
                                     "title":  "Marketing authorisations, variations and licensing guidance",
                                     "web_url":  "https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood-marketing-authorisations-variations-licensing",
                                     "withdrawn":  false
                                 },
                                 {
                                     "api_path":  "/api/content/government/brexit",
                                     "api_url":  "https://www.gov.uk/api/content/government/brexit",
                                     "base_path":  "/government/brexit",
                                     "content_id":  "d6c2de5d-ef90-45d1-82d4-5f2438369eea",
                                     "description":  "Find out how new Brexit rules apply to things like travel and doing business with Europe.",
                                     "details":  {
                                                     "internal_name":  "Brexit",
                                                     "notes_for_editors":  "",
                                                     "url_override":  "/government/collections/brexit-guidance",
                                                     "visible_to_departmental_editors":  true
                                                 },
                                     "document_type":  "taxon",
                                     "links":  {
                                                   "parent_taxons":  [
                                                                         {
                                                                             "api_path":  "/api/content/government/all",
                                                                             "api_url":  "https://www.gov.uk/api/content/government/all",
                                                                             "base_path":  "/government/all",
                                                                             "content_id":  "e48ab80a-de80-4e83-bf59-26316856a5f9",
                                                                             "description":  "",
                                                                             "details":  {
                                                                                             "internal_name":  "Government",
                                                                                             "notes_for_editors":  "",
                                                                                             "visible_to_departmental_editors":  true
                                                                                         },
                                                                             "document_type":  "taxon",
                                                                             "links":  {
                                                                                           "root_taxon":  [
                                                                                                              {
                                                                                                                  "api_path":  "/api/content/",
                                                                                                                  "api_url":  "https://www.gov.uk/api/content/",
                                                                                                                  "base_path":  "/",
                                                                                                                  "content_id":  "f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a",
                                                                                                                  "document_type":  "homepage",
                                                                                                                  "links":  {

                                                                                                                            },
                                                                                                                  "locale":  "en",
                                                                                                                  "public_updated_at":  "2023-06-28T09:32:34Z",
                                                                                                                  "schema_name":  "homepage",
                                                                                                                  "title":  "GOV.UK homepage",
                                                                                                                  "web_url":  "https://www.gov.uk/",
                                                                                                                  "withdrawn":  false
                                                                                                              }
                                                                                                          ]
                                                                                       },
                                                                             "locale":  "en",
                                                                             "phase":  "live",
                                                                             "public_updated_at":  "2018-09-16T20:29:39Z",
                                                                             "schema_name":  "taxon",
                                                                             "title":  "Government",
                                                                             "web_url":  "https://www.gov.uk/government/all",
                                                                             "withdrawn":  false
                                                                         }
                                                                     ]
                                               },
                                     "locale":  "en",
                                     "phase":  "live",
                                     "public_updated_at":  "2024-11-14T17:47:34Z",
                                     "schema_name":  "taxon",
                                     "title":  "Brexit",
                                     "web_url":  "https://www.gov.uk/government/brexit",
                                     "withdrawn":  false
                                 }
                             ]
              },
    "locale":  "en",
    "phase":  "live",
    "public_updated_at":  "2019-10-22T16:28:00+01:00",
    "publishing_app":  "whitehall",
    "publishing_request_id":  "2672-1631014248.302-10.13.4.76-540",
    "publishing_scheduled_at":  null,
    "rendering_app":  "government-frontend",
    "scheduled_publishing_delay_seconds":  null,
    "schema_name":  "detailed_guide",
    "title":  "Comparator products in Bioequivalence/Therapeutic Equivalence studies after Brexit",
    "updated_at":  "2024-11-14T17:48:48+00:00",
    "withdrawn_notice":  {
                             "explanation":  "\u003cdiv class=\"govspeak\"\u003e\u003cp\u003eFor current information on Comparator products in Bioequivalence/Therapeutic Equivalence studies see \u003ca rel=\"external\" href=\"https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/vol2a_chap1_en.pdf\" class=\"govuk-link\"\u003eVolume 2a: Procedures for marketing authorisation\u003c/a\u003e and \u003ca rel=\"external\" href=\"https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-efficacy-safety-clinical-pharmacology-pharmacokinetics\" class=\"govuk-link\"\u003eClinical efficacy and safety: clinical pharmacology and pharmacokinetics\u003c/a\u003e\u003c/p\u003e\n\u003c/div\u003e",
                             "withdrawn_at":  "2020-02-24T10:14:28Z"
                         }
}
